CH Wong, Y Fu, SR Ramisetty… - Nucleic Acids …, 2011 - Oxford Univ Press Myotonic dystrophy type 2 (DM2) is an incurable neuromuscular disease caused by expanded CCUG repeats that may exhibit toxicity by sequestering the splicing regulator MBNL1. A series of triaminotriazine- and triaminopyrimidine-based small molecules (ligands 1–3) were ...
JS Phillips, AI Mallinson… - Current Opinion in …, 2011 - journals.lww.com ... Vestibular evoked myotonicpotential testing. Vestibular evoked myotonicpotential (VEMP) testing is one of the most recent additions to the battery of tests curren.
[PDF] from utoronto.caR Perbellini, S Greco, G Sarra-Ferraris… - Neuromuscular …, 2011 - Elsevier ... males and three females, age = 52 ± 10 years) was based upon the criteria set by the International Consortium for Myotonic Dystrophies [17 ... was functionally relevant, we examined the impact of the identified miRNAs deregulation on the expression of their potential target genes ... Cited by 2 - Related articles - All 5 versions
C Heatwole, N Johnson, B Goldberg… - Archives of …, 2011 - Am Med Assoc ...Myotonic dystrophy type 2 (DM2) is an autosomal dominant muscular dystrophy discovered in 1994. ... This analysis has the potential to (1) further define the clinical manifestations of DM2, (2) discover previously unrecognized areas of DM2 systemic dysfunction, (3) provide a ...
WJ Groh, AJ Moss, EL Logigian… - Neurology, 2011 - AAN Enterprises ... have unduly ac- centuated the potential adverse effects of sodium channel blockers in DM1 based on their unusual case report involving IV procainamide and ... Mexil- etine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology 2010;74:1441–1448. ... Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
